{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Setup"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Import Packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 285,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, json\n",
    "import pandas as pd\n",
    "from typing import Callable, Optional, Dict, Literal, List, Union\n",
    "from pydantic import Field, root_validator\n",
    "\n",
    "from langchain.agents.mrkl.base import ZeroShotAgent\n",
    "from langchain.agents import AgentExecutor\n",
    "from langchain.agents.agent_toolkits.base import BaseToolkit\n",
    "from langchain.base_language import BaseLanguageModel\n",
    "from langchain.callbacks.manager import AsyncCallbackManagerForToolRun, CallbackManagerForToolRun\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.chains import LLMChain, RetrievalQAWithSourcesChain\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.prompts.chat import ChatPromptTemplate, HumanMessagePromptTemplate, SystemMessagePromptTemplate\n",
    "from langchain.tools.base import BaseTool\n",
    "from langchain.utilities.google_serper import GoogleSerperAPIWrapper\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.vectorstores.base import VectorStore\n",
    "\n",
    "from utils import generate_agent_sequence\n",
    "from exp.base import BaseExperiment"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup Directories"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [],
   "source": [
    "MAIN_DIR = \"..\"\n",
    "EMB_DIR = os.path.join(MAIN_DIR, \"data\", \"emb_store\", \"uc\", \"faiss\", \"text-embedding-ada-002\", \"v8-add-tables_2500_500\")\n",
    "\n",
    "with open(os.path.join(MAIN_DIR, \"auth\", \"api_keys.json\"), \"r\") as f:\n",
    "    api_keys = json.load(f)\n",
    "    \n",
    "os.environ[\"OPENAI_API_KEY\"] = api_keys[\"OPENAI_API_KEY\"]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load Test Cases"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 153,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of test cases: 30\n"
     ]
    }
   ],
   "source": [
    "with open(os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all.txt\"),\n",
    "          \"r\", encoding=\"utf-8-sig\") as f:\n",
    "    test_cases = f.readlines()\n",
    "test_cases = [test_case.rstrip() for test_case in test_cases]\n",
    "\n",
    "print(\"Total number of test cases:\", len(test_cases))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# ReAct and MRKL Agents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Toolkit"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "metadata": {},
   "outputs": [],
   "source": [
    "def _print_func(text: str) -> None:\n",
    "    print(\"\\n\")\n",
    "    print(text)\n",
    "    \n",
    "def _get_input() -> str:\n",
    "    print(\"Insert your text. Enter 'q' or press Ctrl-D (or Ctrl-Z on Windows) to end.\")\n",
    "    contents = []\n",
    "    while True:\n",
    "        try:\n",
    "            line = input()\n",
    "        except EOFError:\n",
    "            break\n",
    "        if line == \"q\":\n",
    "            break\n",
    "        contents.append(line)\n",
    "    return \"\\n\".join(contents)\n",
    "\n",
    "class HumanTool(BaseTool):\n",
    "    \"\"\"Tool that asks user for input.\"\"\"\n",
    "\n",
    "    name = \"Human\"\n",
    "    description = (\n",
    "        \"You can ask a human for additional information when you got stuck \"\n",
    "        \"or you are not sure about the treatment recommendation. \"\n",
    "        \"The input should be a question for the human to provide additional \"\n",
    "        \"information about the patient, such as age, gender, whether the patient \"\n",
    "        \"under treatment is a new patient or under maintenance, whether the patient \"\n",
    "        \"has any special response/failure to any drugs or other conditions such as \"\n",
    "        \"pregnancy, extraintestinale manifestations, etc\"\n",
    "    )\n",
    "    prompt_func: Callable[[str], None] = Field(default_factory=lambda: _print_func)\n",
    "    input_func: Callable = Field(default_factory=lambda: _get_input)\n",
    "\n",
    "    def _run(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[CallbackManagerForToolRun] = None,\n",
    "    ) -> str:\n",
    "        \"\"\"Use the Human input tool.\"\"\"\n",
    "        self.prompt_func(query)\n",
    "        return self.input_func()\n",
    "\n",
    "class GeneralKnowledgeTool(BaseTool):\n",
    "    name: str = \"General Knowledge\"\n",
    "    description: str = \"Useful for general knowledge question\"\n",
    "    llm: BaseLanguageModel\n",
    "    \n",
    "    @root_validator()\n",
    "    def initiate_llm_chain(cls, values: Dict) -> Dict:\n",
    "        values[\"llm_chain\"] = LLMChain(\n",
    "            prompt=ChatPromptTemplate.from_messages([HumanMessagePromptTemplate.from_template(\"Question: {question}\")]),\n",
    "            llm=values[\"llm\"]\n",
    "        )\n",
    "        return values\n",
    "    \n",
    "    def _run(\n",
    "        self, \n",
    "        query: str,\n",
    "        run_manager: Optional[CallbackManagerForToolRun] = None\n",
    "        ) -> str:\n",
    "        return self.llm_chain.run(query)\n",
    "    \n",
    "    def _arun(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[AsyncCallbackManagerForToolRun] = None\n",
    "        ) -> str:\n",
    "        return NotImplementedError\n",
    "\n",
    "class QASearchTool(BaseTool):\n",
    "    name: str = \"Docsearch QA Tool\"\n",
    "    description = (\n",
    "        \"Use this tool to search for document and answer questions related to \"\n",
    "        \"treatment of ulcerative colitis from internal database\"\n",
    "    )\n",
    "    llm: BaseLanguageModel\n",
    "    docsearch: VectorStore\n",
    "    prompt_template: Union[ChatPromptTemplate, PromptTemplate]\n",
    "    chain_type: Literal[\"stuff\", \"map_reduce\"] = \"stuff\"\n",
    "    k: int = 4\n",
    "    max_tokens_limit: int = 4500\n",
    "    verbose: bool = True\n",
    "\n",
    "    @root_validator()\n",
    "    def generate_qa_chain(cls, values):\n",
    "        values[\"chain\"] = RetrievalQAWithSourcesChain.from_chain_type(\n",
    "            llm=values[\"llm\"],\n",
    "            chain_type=values[\"chain_type\"],\n",
    "            retriever=values[\"docsearch\"].as_retriever(search_kwargs={\"k\":values[\"k\"]}),\n",
    "            return_source_documents=True,\n",
    "            chain_type_kwargs={\"prompt\": values[\"prompt_template\"]},\n",
    "            reduce_k_below_max_tokens=True,\n",
    "            max_tokens_limit=values[\"max_tokens_limit\"],\n",
    "            verbose=values[\"verbose\"]\n",
    "            )\n",
    "        return values\n",
    "\n",
    "    def _run(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[CallbackManagerForToolRun] = None\n",
    "        ) -> str:\n",
    "        result = self.chain(query)\n",
    "        return result[\"answer\"]\n",
    "\n",
    "    def _arun(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[AsyncCallbackManagerForToolRun] = None\n",
    "        ) -> str:\n",
    "        return NotImplementedError\n",
    "\n",
    "class GoogleSerperTool(BaseTool):\n",
    "    \"\"\"Tool that queries the Serper.dev Google search API.\"\"\"\n",
    "\n",
    "    name = \"google_serper\"\n",
    "    description = (\n",
    "        \"Useful for when you need to search the internet for recommendations on patients profile \"\n",
    "        \"which you don't know about. Input should be a search query.\"\n",
    "    )\n",
    "    serper_api_key: str\n",
    "    \n",
    "    @root_validator()\n",
    "    def initiate_api(cls, values: Dict) -> Dict:\n",
    "        values[\"api_wrapper\"] = GoogleSerperAPIWrapper(serper_api_key=values[\"serper_api_key\"])\n",
    "        return values\n",
    "\n",
    "    def _run(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[CallbackManagerForToolRun] = None,\n",
    "    ) -> str:\n",
    "        \"\"\"Use the tool.\"\"\"\n",
    "        return str(self.api_wrapper.run(query))\n",
    "\n",
    "    async def _arun(\n",
    "        self,\n",
    "        query: str,\n",
    "        run_manager: Optional[AsyncCallbackManagerForToolRun] = None,\n",
    "    ) -> str:\n",
    "        return NotImplementedError\n",
    "    \n",
    "class HumanSearchRetrievalToolkit(BaseToolkit):\n",
    "    serper_api_key: str\n",
    "    llm: BaseLanguageModel\n",
    "    qa_prompt: Union[ChatPromptTemplate, PromptTemplate]\n",
    "    docsearch: VectorStore\n",
    "    k: int = 4\n",
    "    \n",
    "    class Config:\n",
    "        arbitrary_types_allowed = True\n",
    "    \n",
    "    def get_tools(self, tool_names: List = None) -> List[BaseTool]:\n",
    "        all_tools_mapping = {\n",
    "            \"human\": HumanTool(),\n",
    "            \"search\": GoogleSerperTool(serper_api_key=self.serper_api_key),\n",
    "            \"retrieval_qa\": QASearchTool(llm = self.llm, prompt_template = self.qa_prompt, docsearch = self.docsearch, k=self.k),\n",
    "            \"general\": GeneralKnowledgeTool(llm=self.llm)\n",
    "        }\n",
    "        \n",
    "        if not tool_names:\n",
    "            return list(all_tools_mapping.values())\n",
    "        \n",
    "        tools = [all_tools_mapping[tool_name] for tool_name in tool_names]\n",
    "        \n",
    "        return tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 209,
   "metadata": {},
   "outputs": [],
   "source": [
    "docsearch = FAISS.load_local(EMB_DIR, OpenAIEmbeddings())\n",
    "llm = ChatOpenAI(model_name=\"gpt-4\", temperature=0)\n",
    "\n",
    "system_prompt = \"\"\"\n",
    "Make reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\n",
    "You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
    "\n",
    "ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
    "- Whether treated patient is new patient or patient under maintenance\n",
    "- Prior response to Infliximab\n",
    "- Prior failure to Anti-TNF agents\n",
    "- Prior failure to Vedolizumab\n",
    "- Age\n",
    "- Pregnancy\n",
    "- Extraintestinale manifestations\n",
    "- Pouchitis\n",
    "\n",
    "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n",
    "\n",
    "Remember if you are not sure about the answer, just say \"I don't know\", do not make up an answer!\n",
    "\n",
    "{summaries}\n",
    "\"\"\"\n",
    "\n",
    "QA_PROMPT_TEMPLATE = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        SystemMessagePromptTemplate.from_template(\n",
    "            system_prompt, input_variables=[\"summaries\"]\n",
    "        ),\n",
    "        HumanMessagePromptTemplate.from_template(\"{question}\"),\n",
    "    ]\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Use All Tools"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 210,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tool number 1: Docsearch QA Tool\n",
      "Tool number 2: google_serper\n",
      "Tool number 3: General Knowledge\n"
     ]
    }
   ],
   "source": [
    "toolkit = HumanSearchRetrievalToolkit(\n",
    "    serper_api_key=api_keys[\"SERP_API\"],\n",
    "    llm = llm,\n",
    "    qa_prompt = QA_PROMPT_TEMPLATE,\n",
    "    docsearch=docsearch,\n",
    "    k=5\n",
    ")\n",
    "\n",
    "tools = toolkit.get_tools([\"retrieval_qa\", \"search\", \"general\"])\n",
    "for idx, tool in enumerate(tools):\n",
    "    print(f\"Tool number {idx+1}: {tool.name}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Agent Instructions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 211,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are a helpful and honest physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "If you do not know the answer, you will not make up an answer and instead ask further questions for clarifications\n",
      "\n",
      "Your job is to ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "\n",
      "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n",
      "\n",
      "You have access to the following tools:\n",
      "\n",
      "Docsearch QA Tool: Use this tool to search for document and answer questions related to treatment of ulcerative colitis from internal database\n",
      "google_serper: Useful for when you need to search the internet for recommendations on patients profile which you don't know about. Input should be a search query.\n",
      "General Knowledge: Useful for general knowledge question\n",
      "\n",
      "Use the following format:\n",
      "\n",
      "Question: the input question you must answer\n",
      "Thought: you should always think about what to do\n",
      "Action: the action to take, should be one of [Docsearch QA Tool, google_serper, General Knowledge]. Prioritize using Docsearch before using Internet search.\n",
      "Action Input: the input to the action\n",
      "Observation: the result of the action\n",
      "... (this Thought/Action/Action Input/Observation can repeat N times)\n",
      "Thought: I now know the final answer\n",
      "Final Answer: the final answer to the original input question\n",
      "\n",
      "Begin!\n",
      "\n",
      "Patient Profile: {input}\n",
      "Thought: {agent_scratchpad}\n"
     ]
    }
   ],
   "source": [
    "PREFIX = \"\"\"You are a helpful and honest physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
    "If you do not know the answer, you will not make up an answer and instead ask further questions for clarifications\n",
    "\n",
    "Your job is to ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
    "- Whether treated patient is new patient or patient under maintenance\n",
    "- Prior response to Infliximab\n",
    "- Prior failure to Anti-TNF agents\n",
    "- Prior failure to Vedolizumab\n",
    "- Age\n",
    "- Pregnancy\n",
    "- Extraintestinale manifestations\n",
    "- Pouchitis\n",
    "\n",
    "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n",
    "\n",
    "You have access to the following tools:\"\"\"\n",
    "\n",
    "FORMAT_INSTRUCTIONS = \"\"\"Use the following format:\n",
    "\n",
    "Question: the input question you must answer\n",
    "Thought: you should always think about what to do\n",
    "Action: the action to take, should be one of [{tool_names}]. Prioritize using Docsearch before using Internet search.\n",
    "Action Input: the input to the action\n",
    "Observation: the result of the action\n",
    "... (this Thought/Action/Action Input/Observation can repeat N times)\n",
    "Thought: I now know the final answer\n",
    "Final Answer: the final answer to the original input question\"\"\"\n",
    "\n",
    "SUFFIX = \"\"\"Begin!\n",
    "\n",
    "Patient Profile: {input}\n",
    "Thought: {agent_scratchpad}\"\"\"\n",
    "\n",
    "AGENT_PROMPT_1 = ZeroShotAgent.create_prompt(\n",
    "    tools=tools,\n",
    "    prefix=PREFIX,\n",
    "    suffix=SUFFIX,\n",
    "    format_instructions=FORMAT_INSTRUCTIONS,    \n",
    ")\n",
    "\n",
    "print(AGENT_PROMPT_1.template)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Agent Executor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "metadata": {},
   "outputs": [],
   "source": [
    "agent_llm = LLMChain(\n",
    "    llm = ChatOpenAI(model_name = \"gpt-4\", temperature = 0, max_tokens = 256),\n",
    "    prompt = AGENT_PROMPT_1\n",
    ")\n",
    "\n",
    "REACT_AGENT_1 = ZeroShotAgent(llm_chain=agent_llm, allowed_tools = [tool.name for tool in tools])\n",
    "\n",
    "agent_args = {\n",
    "    \"max_iterations\": 5,\n",
    "    \"early_stopping_method\": \"generate\",\n",
    "    \"return_intermediate_steps\": True\n",
    "    }\n",
    "agent_executor = AgentExecutor.from_agent_and_tools(agent=REACT_AGENT_1, tools=tools, verbose=True, **agent_args)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Run Test Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [],
   "source": [
    "results = [None] * 30"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is newly diagnosed with moderate ulcerative colitis and has extraintestinal manifestations in the form of joint issues. I need to consider the best biological drugs for this patient. I will use the Docsearch QA Tool to find the best treatment options for a newly diagnosed patient with these conditions.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best biological drugs for a newly diagnosed patient with moderate ulcerative colitis and articular extraintestinal manifestations?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[38;5;200m\u001b[1;3mBased on the data provided, Infliximab and Vedolizumab could be considered as the top choices for a newly diagnosed patient with moderate ulcerative colitis.\n",
      "\n",
      "Infliximab was ranked highest for efficacy in biologic-naïve patients, meaning it has been shown to be very effective in inducing remission in patients who have not been previously treated with biological drugs. It targets the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), which is implicated in the inflammation associated with ulcerative colitis. The pros of Infliximab include its high efficacy and the fact that it has been around for a while, so its effects and side effects are well-studied. The cons include the potential for adverse reactions, the need for parenteral administration, and the fact that some patients may not respond to the drug.\n",
      "\n",
      "Vedolizumab is another option that has been approved for the treatment of ulcerative colitis. It targets α or β integrins, which are involved in the migration of immune cells to inflamed intestinal mucosa. The pros of Vedolizumab include its efficacy and its different mechanism of action, which may make it a good option for patients who do not respond to or cannot tolerate TNF-α inhibitors. The cons again include potential side effects, the need for parenteral administration, and the fact that it may not work for all patients.\n",
      "\n",
      "As for the articular extraintestinal manifestations, both Infliximab and Vedolizumab have been shown to be effective in managing these manifestations. However, the decision on which drug to use should be made considering the patient's overall health status, potential side effects, and personal preferences.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer.\n",
      "Final Answer: The top two choices of biological drugs for this patient are Infliximab and Vedolizumab. \n",
      "\n",
      "Infliximab has high efficacy in inducing remission in patients who have not been previously treated with biological drugs. It targets the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), which is implicated in the inflammation associated with ulcerative colitis. The pros of Infliximab include its high efficacy and the fact that it has been around for a while, so its effects and side effects are well-studied. The cons include the potential for adverse reactions, the need for parenteral administration, and the fact that some patients may not respond to the drug.\n",
      "\n",
      "Vedolizumab targets α or β integrins, which are involved in the migration of immune cells to inflamed intestinal mucosa. The pros of Vedolizumab include its efficacy and its different mechanism of action, which may make it a good option for patients who do not respond to or cannot tolerate TNF-α inhibitors. The cons again include potential side effects, the need for parenteral administration, and the fact that it may not work for all patients.\n",
      "\n",
      "Both Infliximab and Vedolizumab have been shown to be effective in managing articular extraintestinal manifestations. However, the decision on which drug to use should be made considering the patient's overall health status, potential side effects, and personal preferences.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[0]\n",
    "results[0] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 224,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 70 year old female with newly diagnosed severe UC\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is newly diagnosed with severe ulcerative colitis and is of an older age. I need to consider the age factor and the severity of the disease while recommending biological drugs. I will use the Docsearch QA Tool to find the best treatment options for this patient profile.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for a newly diagnosed, severe ulcerative colitis in a 70 year old female patient? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, two top choices of biological drugs for a newly diagnosed, severe ulcerative colitis in a 70-year-old female patient could be Infliximab and Upadacitinib.\n",
      "\n",
      "1. Infliximab: This drug targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which has demonstrated efficacy in clinical trials in moderate to severe UC. It is ranked first for endoscopic improvement, which is a key factor in managing severe UC.\n",
      "\n",
      "   Pros: Infliximab has been shown to be effective in inducing and maintaining remission in patients with moderate to severe UC. It can lead to endoscopic improvement, which is crucial in managing severe UC.\n",
      "\n",
      "   Cons: Infliximab is administered intravenously, which may be inconvenient for some patients. There may also be risks associated with its use, such as infections and other potential side effects.\n",
      "\n",
      "2. Upadacitinib: This is a newer drug that has shown efficacy in phase III clinical trials. It ranked first for clinical remission in all patients, including those who are new to anti-TNF-α drugs.\n",
      "\n",
      "   Pros: Upadacitinib has been shown to be highly effective in achieving clinical remission. It is also effective in patients who are new to anti-TNF-α drugs.\n",
      "\n",
      "   Cons: Upadacitinib was more likely to lead to adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo. \n",
      "\n",
      "It's important to note that the choice of treatment should be individualized based on the patient's overall health, comorbidities, and preferences. The patient's age may also influence the choice of treatment, as older patients may have a higher risk of adverse events. Therefore, a thorough discussion with the patient is necessary before starting treatment.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: For a 70-year-old female patient newly diagnosed with severe ulcerative colitis, the top two choices of biological drugs could be Infliximab and Upadacitinib. \n",
      "\n",
      "Infliximab is effective in inducing and maintaining remission and can lead to endoscopic improvement, which is crucial in managing severe UC. However, it is administered intravenously, which may be inconvenient, and there may be risks such as infections and other potential side effects.\n",
      "\n",
      "Upadacitinib has been shown to be highly effective in achieving clinical remission and is also effective in patients who are new to anti-TNF-α drugs. However, it was more likely to lead to adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo. \n",
      "\n",
      "The choice of treatment should be individualized based on the patient's overall health, comorbidities, and preferences. The patient's age may also influence the choice of treatment, as older patients may have a higher risk of adverse events. Therefore, a thorough discussion with the patient is necessary before starting treatment.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[1]\n",
    "print(\"Patient Profile:\", sample_case)\n",
    "results[1] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 55 year-old man with moderate to severe extensive ulcerative colitis who avlues convenience and limited time spent in hospital\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is middle-aged and has moderate to severe ulcerative colitis. He prefers convenience and limited hospital time. I need to consider these factors when recommending biological drugs. I will first use the Docsearch QA Tool to find suitable treatments for this patient profile.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for a 55 year-old man with moderate to severe extensive ulcerative colitis who values convenience and limited time spent in hospital?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the information provided, two top choices of biological drugs for this patient could be Upadacitinib and Infliximab.\n",
      "\n",
      "1. Upadacitinib: This drug ranked first in terms of clinical remission in all patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these drugs. It was also superior to almost all other drugs in these analyses. However, it was more likely to lead to adverse events, but serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "Pros: High efficacy in achieving clinical remission, can be used in patients with prior exposure to anti-TNF-α therapies, lower withdrawal rate due to adverse events.\n",
      "Cons: Higher likelihood of adverse events, although not serious ones.\n",
      "\n",
      "2. Infliximab: This drug ranked first in terms of endoscopic improvement. It was also ranked second and third for clinical remission.\n",
      "\n",
      "Pros: High efficacy in achieving endoscopic improvement, good efficacy in achieving clinical remission.\n",
      "Cons: It is administered intravenously which may not be convenient for patients who value limited time spent in hospital.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with his healthcare provider to make the best decision.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: Based on the patient's profile and preferences, the top two choices of biological drugs could be Upadacitinib and Infliximab. \n",
      "\n",
      "Upadacitinib has high efficacy in achieving clinical remission and can be used in patients with prior exposure to anti-TNF-α therapies. It also has a lower withdrawal rate due to adverse events. However, it may lead to a higher likelihood of adverse events, although not serious ones.\n",
      "\n",
      "Infliximab has high efficacy in achieving endoscopic improvement and good efficacy in achieving clinical remission. However, it is administered intravenously which may not be convenient for patients who value limited time spent in hospital.\n",
      "\n",
      "The choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with his healthcare provider to make the best decision.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[14]\n",
    "print(\"Patient Profile:\", sample_case)\n",
    "results[14] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 227,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 53 year-old man with moderate to severe extensive ulcerative colitis and low albumin levels\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is middle-aged and has moderate to severe ulcerative colitis. The low albumin levels indicate that the disease is active and the patient is losing protein. I need to consider the patient's age, disease severity, and albumin levels when recommending treatment. I will use the Docsearch QA Tool to find the best biological drugs for this patient profile.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best biological drugs for a 53 year-old man with moderate to severe extensive ulcerative colitis and low albumin levels? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, it's not clear whether the patient has been previously exposed to anti-TNF-α therapies or not. However, considering the general data from the studies, two top choices could be:\n",
      "\n",
      "1. Upadacitinib 45mg o.d.: This drug ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to these drugs. It was also superior to almost all other drugs in these analyses. However, it was more likely to lead to adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "2. Infliximab 10mg/kg: This drug ranked first for endoscopic improvement. It was also ranked second for achieving clinical remission. \n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, comorbidities, and preferences. It's also important to consider the potential side effects and risks associated with each treatment option.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe Docsearch QA Tool has provided two potential biological drugs for this patient: Upadacitinib and Infliximab. Both drugs have shown effectiveness in treating moderate to severe ulcerative colitis. However, Upadacitinib may lead to more adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo. Infliximab, on the other hand, ranked first for endoscopic improvement and second for achieving clinical remission. I will now provide the pros and cons of these two drugs.\n",
      "Final Answer: The top two choices of biological drugs for this patient are Upadacitinib and Infliximab.\n",
      "\n",
      "1. Upadacitinib: \n",
      "   Pros: It ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to these drugs. It was also superior to almost all other drugs in these analyses. Withdrawals due to adverse events were significantly lower than with placebo.\n",
      "   Cons: It was more likely to lead to adverse events, although serious adverse events were no more frequent.\n",
      "\n",
      "2. Infliximab:\n",
      "   Pros: This drug ranked first for endoscopic improvement. It was also ranked second for achieving clinical\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[18]\n",
    "print(\"Patient Profile:\", sample_case)\n",
    "results[18] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 228,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 42 year-old woman with severe ulcerative colitis and rare fistulating disease\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has severe ulcerative colitis and a rare fistulating disease. I need to consider the severity of the disease, the presence of the fistulating disease, and the patient's age and gender. I will first use the Docsearch QA Tool to find the best biological drugs for severe ulcerative colitis.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best biological drugs for severe ulcerative colitis?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, two top choices of biological drugs for moderate to severe ulcerative colitis could be Infliximab and Upadacitinib.\n",
      "\n",
      "1. Infliximab: \n",
      "   - Pros: Infliximab has demonstrated efficacy in clinical trials for moderate to severe UC. It targets the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which plays a significant role in the inflammation process of UC. For endoscopic improvement, Infliximab 10mg/kg ranked first. It is also recommended as a first-line therapy for biologic-naïve patients.\n",
      "   - Cons: Infliximab, like other biological therapies, may not work in all patients. There may be risks associated with its use, and it is administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "2. Upadacitinib:\n",
      "   - Pros: Upadacitinib 45mg o.d. ranked first in terms of clinical remission and clinical response in all patients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these drugs. For endoscopic improvement, Upadacitinib 45mg o.d. ranked first in patients previously exposed to anti-TNF-α therapies, and in patients who were anti-TNF-α naïve. It was also found to be significantly superior to all other interventions for the induction of clinical remission.\n",
      "   - Cons: While the document does not specify any cons for Upadacitinib, it's important to note that, like all medications, it may have potential side effects and may not work for all patients. It's also worth noting that the convenience of administration and potential risks associated with its use are not specified in the document. \n",
      "\n",
      "Please consult with a healthcare provider for personalized medical advice.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the top two choices of biological drugs for severe ulcerative colitis, which are Infliximab and Upadacitinib. However, I need to consider the patient's rare fistulating disease. I will use the Docsearch QA Tool again to find out if these drugs are suitable for patients with fistulating disease.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Are Infliximab and Upadacitinib suitable for patients with fistulating disease?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mThe provided documents do not contain specific information about the use of Infliximab and Upadacitinib in patients with fistulating disease.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe documents do not provide information on the use of Infliximab and Upadacitinib in patients with fistulating disease. I will use the google_serper tool to find more information.\n",
      "Action: google_serper\n",
      "Action Input: Infliximab and Upadacitinib for fistulating disease treatment\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mInfliximab is an efficacious treatment for fistulas in patients with Crohn's disease. Missing: Upadacitinib | Show results with:Upadacitinib. Upadacitinib was approved by the FDA in March 2022 for the treatment of adults with moderately to severely active UC who had an inadequate response or ... The combined treatment with adalimumab and ciprofloxacin seems to be superior to an anti-TNF treatment only; however, the positive effect is ... Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn's ... Missing: Upadacitinib | Show results with:Upadacitinib. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of Crohn's ... In RA, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating ... The patient is a male with fistulizing Crohn's disease and Rheumatoid Arthritis. ... Remicade, and high-dose Entyvio for the treatment of Crohn's disease. We evaluated rates of fistula and fissure improvements with upadacitinib (UPA), an oral selective Janus kinase inhibitor, in patients with CD who had fistulas ... Missing: Infliximab | Show results with:Infliximab. This algorithm is a tool to aid the implementation of NICE guidance for high cost medicines used in the treatment of severe active Crohn's disease and ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the information found, Infliximab is an effective treatment for fistulas in patients with Crohn's disease, which is a similar condition to ulcerative colitis. Upadacitinib has been used in patients with Crohn's disease who had fistulas, but there is less information available about its effectiveness in this context. Given this information, Infliximab and Upadacitinib could be potential treatment options for this patient. However, the final decision should be made in consultation with the patient's healthcare provider, taking into account the patient's overall health status and preferences.\n",
      "Final Answer: The top two choices of biological drugs for this patient with severe ulcerative colitis and a rare fistulating disease are Infliximab and Upadacitinib. \n",
      "\n",
      "1. Infliximab: \n",
      "   - Pros: Infliximab has demonstrated efficacy in clinical trials for moderate to severe UC and is also an effective treatment for fistulas in patients with Crohn's disease. It is recommended as a first-line therapy for biologic-naïve patients.\n",
      "   - Cons: Infliximab may not work in all patients and there may be risks associated with its use. It is administered either intravenously or subcutaneously, which\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[19]\n",
    "print(\"Patient Profile:\", sample_case)\n",
    "results[19] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 229,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 68 year-old man with extensive moderate to severe ulcerative colitis who has prostate cancer which has been treated 5 years ago.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is elderly and has a history of prostate cancer. His ulcerative colitis is extensive and moderate to severe. I need to consider his age and cancer history when recommending biological drugs. I will use the Docsearch QA Tool to find suitable treatments for this patient profile.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Treatment for moderate to severe ulcerative colitis in elderly patients with history of cancer\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI'm sorry, but the documents provided do not contain specific information about the treatment of moderate to severe ulcerative colitis in elderly patients with a history of cancer.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe documents did not provide specific information for this patient's profile. I will now use the google_serper tool to find more information.\n",
      "Action: google_serper\n",
      "Action Input: Treatment for moderate to severe ulcerative colitis in elderly patients with history of cancer\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mFrom a safety profile perspective, vedolizumab, ustekinumab, and risankizumab should be considered first line treatment options for moderate-to- ... Although the ECCO Malignancy Consensus guidelines outline that 5-aminosalicylates and local steroid therapy (budesonide) are safe to use in ... The safety of IBD treatments is the biggest concern, especially when immunosuppressants therapies are used to achieve and maintain disease ... Background and Aim: The aim of this study was to compare therapeutic responses and prognosis between elderly and nonelderly ulcerative ... Anti-TNF agents are used in moderate to severe CD and UC and are effective in inducing clinical and endoscopic remission, decreasing rates of ... Thiopurine (6-mercaptopurine, azathioprine) has been proven to be effective and safe for maintaining remission in moderate to severe ... Topical corticosteroids (or aminosalicylates) may be effective for distal colonic disease but may be poorly tolerated in older patients with ... Multimorbidity limits medical therapy. This determines a major number of complications that can't be treated with medical therapy, and they ... The therapeutic management of older patients with inflammatory bowel disease (IBD) is challenging, particularly because of the absence of evidence-based ... The role of anti-TNF therapy in the decisive induction and maintenance of remission in moderate to severely active IBD has been established ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, vedolizumab, ustekinumab, and risankizumab are considered first line treatment options for moderate-to-severe ulcerative colitis in patients with a history of cancer due to their safety profile. Anti-TNF agents are also effective in inducing clinical and endoscopic remission, but their safety in patients with a history of cancer is not clear. I will now analyze the pros and cons of vedolizumab and ustekinumab, as these two drugs were mentioned first in the search results.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Pros and cons of vedolizumab and ustekinumab for treatment of moderate to severe ulcerative colitis\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mVedolizumab and Ustekinumab are both effective treatments for moderate to severe ulcerative colitis. \n",
      "\n",
      "Vedolizumab Pros:\n",
      "1. It is a gut-selective immunosuppressant, meaning it specifically targets the gut and spares the rest of the body from immunosuppression. This can potentially reduce the risk of systemic side effects.\n",
      "2. It has been shown to be more effective than adalimumab for long-term maintenance of clinical remission.\n",
      "\n",
      "Vedolizumab Cons:\n",
      "1. It may not be as effective in patients with prior exposure to TNF antagonists.\n",
      "2. It may not be as effective as other treatments for inducing clinical remission.\n",
      "\n",
      "Ustekinumab Pros:\n",
      "1. It has been ranked highest for inducing clinical remission in patients with prior exposure to TNF antagonists.\n",
      "2. It has been shown to be superior to vedolizumab and adalimumab for induction of clinical remission in patients with prior exposure to TNF antagonists.\n",
      "\n",
      "Ustekinumab Cons:\n",
      "1. It is a systemic immunosuppressant, which means it suppresses the immune system throughout the entire body. This can potentially lead to an increased risk of infections and other side effects.\n",
      "2. The long-term safety profile of ustekinumab is not as well established as some other treatments.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: Based on the patient's profile and the information gathered, the top two choices of biological drugs for this patient would be Vedolizumab and Ustekinumab.\n",
      "\n",
      "Vedolizumab Pros:\n",
      "1. It is a gut-selective immunosuppressant, meaning it specifically targets the gut and spares the rest of the body from immunosuppression. This can potentially reduce the risk of systemic side effects, which is beneficial for an elderly patient with a history of cancer.\n",
      "2. It has been shown to be more effective than adalimumab for long-term maintenance of clinical remission.\n",
      "\n",
      "Vedolizumab Cons:\n",
      "1. It may not be as effective in patients with prior exposure to TNF antagonists.\n",
      "2. It may not be as effective as other treatments for inducing clinical remission.\n",
      "\n",
      "Ustekinumab Pros:\n",
      "1. It has been ranked highest for inducing clinical remission in patients with prior exposure to TNF antagonists.\n",
      "2. It has been shown to be superior to vedolizumab and adalimumab for induction of clinical remission in patients with prior exposure to TNF antagonists.\n",
      "\n",
      "Ustekinumab Cons:\n",
      "\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[20]\n",
    "print(\"Patient Profile:\", sample_case)\n",
    "results[20] = agent_executor(sample_case)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 242,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"I'm sorry, but the documents provided do not contain specific information about the treatment of moderate to severe ulcerative colitis in elderly patients with a history of cancer.\""
      ]
     },
     "execution_count": 242,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results[20][\"intermediate_steps\"][0][1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 246,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Profile: 44 year-old woman with moderate to severe extensive ulcerative colitis and rheumatoid arthritis.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe ulcerative colitis and rheumatoid arthritis. I need to consider the patient's age, the severity of her conditions, and the fact that she has two autoimmune diseases. I should look for biological drugs that can treat both conditions.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for treating moderate to severe ulcerative colitis and rheumatoid arthritis? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI don't know\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI didn't get the information I needed from the Docsearch QA Tool. I should try using the internet search to find the recommended biological drugs for treating moderate to severe ulcerative colitis and rheumatoid arthritis.\n",
      "Action: google_serper\n",
      "Action Input: Recommended biological drugs for treating moderate to severe ulcerative colitis and rheumatoid arthritis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mBiologic drugs, such as Humira (adalimumab), Simponi (golimumab), Remicade (infliximab), Entyvio (vedolizumab), and Stelara (ustekinumab), can alleviate inflammation and keep your disease in remission if other UC medications aren't effective. Jun 1, 2023\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, Humira (adalimumab), Simponi (golimumab), Remicade (infliximab), Entyvio (vedolizumab), and Stelara (ustekinumab) are potential options for treating moderate to severe ulcerative colitis. However, I need to consider which of these are also effective for treating rheumatoid arthritis.\n",
      "Action: google_serper\n",
      "Action Input: Which biological drugs are effective for both ulcerative colitis and rheumatoid arthritis?\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mBiological agents have been used for UC treatment for 10 years, and various types of biological agents have been developed and used worldwide, with the most ... The treatment armamentarium includes small molecules and biological treatments. Small molecules include classical drugs such as mesalazine, ... 1. Biologics Aren't Considered a First-Line Treatment · 5 Complications of Ulcerative Colitis · 2. Biologics Are Targeted Medications · 3. Stelara is the new biologic on the block. While the drug has been on the market since 2009 for the treatment of Crohn's disease, psoriatic ... This drug can be suitable for people with an intolerance to anti-TNF agents or people who did not find these drugs to be effective. It may also benefit people ... Information about biologic medicines, a form of treatment for Crohn's and Colitis (the two main forms of Inflammatory Bowel Disease - IBD) Missing: rheumatoid | Show results with:rheumatoid. Biologic drugs approved by the FDA for treating ulcerative colitis include: Anti-TNF agents: Humira (adalimumab), Simponi (golimumab), and ... These drugs ease inflammation by changing how your immune system works. Combination therapy might help your UC treatment work better. But you ... Disease-modifying antirheumatic drugs (DMARDs) are a group of medications commonly used in people with rheumatoid arthritis. The patient was intolerant to multiple disease-modifying drugs, so Tocilizumab monotherapy was commenced. We found clinical improvement in both RA and UC.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, Humira (adalimumab) and Simponi (golimumab) are both anti-TNF agents that are approved for treating ulcerative colitis and rheumatoid arthritis. However, the patient's tolerance and response to these drugs should be considered. I will choose these two drugs as the top choices for this patient.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the pros and cons of Humira (adalimumab) and Simponi (golimumab) for treating ulcerative colitis and rheumatoid arthritis?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI'm sorry, but the provided context does not contain specific information about the pros and cons of Humira (adalimumab) and Simponi (golimumab) for treating ulcerative colitis and rheumatoid arthritis.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe Docsearch QA Tool did not provide the specific information I needed. I should use the internet search to find the pros and cons of Humira (adalimumab) and Simponi (golimumab) for treating ulcerative colitis and rheumatoid arthritis.\n",
      "Action: google_serper\n",
      "Action Input: Pros and cons of Humira (adalimumab) and Simponi (golimumab) for treating ulcerative colitis and rheumatoid arthritis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mSimponi (golimumab) is an injectable medication used to treat many autoimmune conditions, including different kinds of arthritis and ulcerative colitis (UC) ... Prescription only. Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, ... Missing: Pros | Show results with:Pros. The biologics that are now approved by the U.S. Food and Drug Administration (FDA) for treating ulcerative colitis include: Humira (adalimumab) ... This review summarizes all available efficacy and safety data of golimumab in UC and analyzes its therapeutic position for the treatment of ... Humira® is a prescription medicine used in adults to help get moderate to severe UC under control (induce remission) and keep it under control (sustain ... Missing: Pros | Show results with:Pros. Humira (adalimumab) is a prescription injection used to treat rheumatoid arthritis and other conditions. Learn about side effects, cost, uses, and more. Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further ... HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe ... HUMIRA is a prescription medicine used to treat moderate to severe ulcerative colitis in adults and children 5 years of age and older. It is not known if HUMIRA ... HUMIRA is a prescription medication that targets and blocks a source of inflammation caused by moderate to severe ulcerative colitis (UC).\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mFinal Answer: The top two choices of biological drugs for this patient are Humira (adalimumab) and Simponi (golimumab). \n",
      "\n",
      "Pros of Humira (adalimumab): \n",
      "- It is approved for treating both ulcerative colitis and rheumatoid arthritis. \n",
      "- It can help get moderate to severe ulcerative colitis under control and keep it under control. \n",
      "- It can be used alone or with certain other medicines. \n",
      "\n",
      "Cons of Humira (adalimumab): \n",
      "- It is a prescription injection, which some patients may find inconvenient or uncomfortable. \n",
      "- Potential side effects need to be considered and monitored. \n",
      "\n",
      "Pros of Simponi (golimumab): \n",
      "- It is also approved for treating both ulcerative colitis and rheumatoid arthritis. \n",
      "- It is an injectable medication, which can be more convenient for some patients. \n",
      "\n",
      "Cons of Simponi (golimumab): \n",
      "- It is a prescription medication, which requires regular doctor visits and monitoring. \n",
      "- Potential side effects need to be considered and monitored. \n",
      "\n",
      "It's important to note that the patient's tolerance and response to these drugs should be considered, and the treatment plan should be individualized based on the patient's specific needs\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 60 year-old woman with severe ulcerative colitis that has loss response to anti-TNF, vedolizumab and ustekinumab\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has severe ulcerative colitis and has lost response to anti-TNF, vedolizumab, and ustekinumab. I need to consider other biological drugs that could be effective for her. I will use the Docsearch QA Tool to find suitable alternatives.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the alternative biological drugs for ulcerative colitis in patients who have lost response to anti-TNF, vedolizumab, and ustekinumab?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided documents, the alternative biological drugs for ulcerative colitis in patients who have lost response to anti-TNF, vedolizumab, and ustekinumab could be tofacitinib and upadacitinib. \n",
      "\n",
      "Tofacitinib and upadacitinib are both small molecule drugs that have been shown to be effective in treating moderate to severe ulcerative colitis. \n",
      "\n",
      "Pros of Tofacitinib:\n",
      "- It is a Janus kinase (JAK) inhibitor that has been approved for the treatment of moderate-to-severe ulcerative colitis.\n",
      "- It can be administered orally and on a daily basis, which may be more convenient for patients.\n",
      "\n",
      "Cons of Tofacitinib:\n",
      "- As a relatively new drug, long-term safety data may not be as robust as for older drugs.\n",
      "- It may have potential side effects, including serious infections, malignancies, and thrombosis.\n",
      "\n",
      "Pros of Upadacitinib:\n",
      "- It has shown efficacy in phase III clinical trials for the treatment of ulcerative colitis.\n",
      "- Like tofacitinib, it can be administered orally and on a daily basis.\n",
      "\n",
      "Cons of Upadacitinib:\n",
      "- It is still in the late stages of development and may not yet be available in all regions.\n",
      "- Potential side effects and long-term safety data are not fully known yet.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: The top two choices of biological drugs for this patient could be Tofacitinib and Upadacitinib. \n",
      "\n",
      "Tofacitinib Pros: \n",
      "- Approved for the treatment of moderate-to-severe ulcerative colitis\n",
      "- Can be administered orally and on a daily basis, which may be more convenient for patients.\n",
      "\n",
      "Tofacitinib Cons: \n",
      "- As a relatively new drug, long-term safety data may not be as robust as for older drugs.\n",
      "- It may have potential side effects, including serious infections, malignancies, and thrombosis.\n",
      "\n",
      "Upadacitinib Pros: \n",
      "- It has shown efficacy in phase III clinical trials for the treatment of ulcerative colitis.\n",
      "- Like tofacitinib, it can be administered orally and on a daily basis.\n",
      "\n",
      "Upadacitinib Cons: \n",
      "- It is still in the late stages of development and may not yet be available in all regions.\n",
      "- Potential side effects and long-term safety data are not fully known yet.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe ulcerative colitis and spondylarthristis. I need to consider the patient's age, the severity of his condition, and the presence of extraintestinal manifestations (spondylarthristis) in recommending a biological drug. I will use the Docsearch QA Tool to find the best treatment options for this patient.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for a 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI don't know\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI didn't get any results from the Docsearch QA Tool. I will try to use the google_serper to find the best treatment options for this patient.\n",
      "Action: google_serper\n",
      "Action Input: Recommended biological drugs for a 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mBiologic/Biosimilar Therapies  * Adalimumab.  * Golimumab.  * Infliximab.  * Ustekinumab.  * Vedolizumab.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, the recommended biological drugs for a 36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis are Adalimumab, Golimumab, Infliximab, Ustekinumab, and Vedolizumab. I will now analyze the pros and cons of the top two choices.\n",
      "Action: General Knowledge\n",
      "Action Input: Pros and cons of Adalimumab and Golimumab for treating moderate to severe extensive ulcerative colitis and spondylarthristis.\u001b[0m\n",
      "Observation: \u001b[38;5;200m\u001b[1;3mAdalimumab and Golimumab are both types of tumor necrosis factor (TNF) inhibitors, which are used to treat inflammatory conditions such as ulcerative colitis and spondylarthristis. They work by blocking the action of TNF, a substance in the body that causes inflammation.\n",
      "\n",
      "Adalimumab (Humira) Pros:\n",
      "1. It has been shown to be effective in reducing symptoms and inducing and maintaining remission in patients with moderate to severe ulcerative colitis.\n",
      "2. It can also reduce the signs and symptoms of spondylarthristis and can slow the progression of joint damage.\n",
      "3. It can be self-administered at home.\n",
      "\n",
      "Adalimumab Cons:\n",
      "1. It can cause serious side effects, including infections (such as tuberculosis), malignancies (such as lymphoma), and demyelinating disorders.\n",
      "2. It can cause injection site reactions.\n",
      "3. It requires regular, often weekly, injections.\n",
      "\n",
      "Golimumab (Simponi) Pros:\n",
      "1. It has been shown to be effective in reducing symptoms and inducing and maintaining remission in patients with moderate to severe ulcerative colitis.\n",
      "2. It can also reduce the signs and symptoms of spondylarthristis and can slow the progression of joint damage.\n",
      "3. It is administered less frequently than Adalimumab, usually once a month.\n",
      "\n",
      "Golimumab Cons:\n",
      "1. It can cause serious side effects, including infections (such as tuberculosis), malignancies (such as lymphoma), and demyelinating disorders.\n",
      "2. It can cause injection site reactions.\n",
      "3. It is more expensive than other TNF inhibitors.\n",
      "\n",
      "In conclusion, both Adalimumab and Golimumab have been shown to be effective in treating moderate to severe ulcerative colitis and spondylarthristis. However, they can cause serious side effects and require regular injections. The choice between the two will depend on the individual patient's condition, tolerance for side effects, and ability to adhere to the treatment regimen.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: The top two choices of biological drugs for this patient are Adalimumab and Golimumab. \n",
      "\n",
      "Adalimumab Pros: \n",
      "1. Effective in reducing symptoms and inducing and maintaining remission in patients with moderate to severe ulcerative colitis.\n",
      "2. Reduces the signs and symptoms of spondylarthristis and can slow the progression of joint damage.\n",
      "3. Can be self-administered at home.\n",
      "\n",
      "Adalimumab Cons:\n",
      "1. Can cause serious side effects, including infections (such as tuberculosis), malignancies (such as lymphoma), and demyelinating disorders.\n",
      "2. Can cause injection site reactions.\n",
      "3. Requires regular, often weekly, injections.\n",
      "\n",
      "Golimumab Pros:\n",
      "1. Effective in reducing symptoms and inducing and maintaining remission in patients with moderate to severe ulcerative colitis.\n",
      "2. Reduces the signs and symptoms of spondylarthristis and can slow the progression of joint damage.\n",
      "3. Administered less frequently than Adalimumab, usually once a month.\n",
      "\n",
      "Golimumab Cons:\n",
      "1. Can cause serious side effects, including infections (such as tuberculosis), malignancies (such as lymphoma), and demyelinating disorders\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 42 year-old woman with moderate ulcerative colitis on azathioprine and not responding to therapy\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is not responding to current therapy, so we need to consider alternative treatments. As a physician assistant, I know that biological drugs are often used in moderate to severe ulcerative colitis cases. However, I need to consider the patient's age, prior response to certain drugs, and any other relevant factors before making a recommendation.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for moderate to severe ulcerative colitis in a 42-year-old woman not responding to azathioprine? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, the top two choices of biological drugs for a 42-year-old woman with moderate to severe ulcerative colitis not responding to azathioprine could be:\n",
      "\n",
      "1. Upadacitinib 45mg once daily: This drug has been ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to these drugs. It has shown superiority to almost all other drugs in these analyses. However, it was more likely to lead to adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "Pros: Effective in inducing clinical remission, can be used in patients with prior exposure to anti-TNF-α drugs, lower withdrawal rate due to adverse events.\n",
      "Cons: More likely to lead to adverse events.\n",
      "\n",
      "2. Infliximab 10mg/kg: This drug has been ranked first for endoscopic improvement, which is an important aspect of managing ulcerative colitis. It has also demonstrated efficacy in clinical trials in moderate to severe UC.\n",
      "\n",
      "Pros: Effective in inducing endoscopic improvement, proven efficacy in clinical trials.\n",
      "Cons: It is administered either intravenously or subcutaneously, which may be inconvenient for some patients. \n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects. It's also important to consider the patient's prior response to anti-TNF agents, as this can influence the effectiveness of these drugs.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: The top two choices of biological drugs for a 42-year-old woman with moderate to severe ulcerative colitis not responding to azathioprine could be Upadacitinib 45mg once daily and Infliximab 10mg/kg. \n",
      "\n",
      "Upadacitinib has been ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to these drugs. It has shown superiority to almost all other drugs in these analyses. However, it was more likely to lead to adverse events, although serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "Infliximab has been ranked first for endoscopic improvement, which is an important aspect of managing ulcerative colitis. It has also demonstrated efficacy in clinical trials in moderate to severe UC. However, it is administered either intravenously or subcutaneously, which may be inconvenient for some patients. \n",
      "\n",
      "The choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects. It's also important to consider the patient's prior response to anti-TNF agents, as this can influence the effectiveness of these drugs\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 25 year-old man with extensive moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis. I need to consider the patient's age, the severity of his condition, and his liver disease when recommending biological drugs. I will use the Docsearch QA Tool to find the best treatment options for this patient.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best biological drugs for a 25 year-old man with moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI'm sorry, but the documents provided do not contain specific information about the best biological drugs for a 25 year-old man with moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe Docsearch QA Tool did not provide the specific information I need. I will now use the google_serper tool to search the internet for recommendations.\n",
      "Action: google_serper\n",
      "Action Input: Best biological drugs for moderate to severe ulcerative colitis in a patient with primary sclerosing cholangitis and decompensated cirrhosis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3m... and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, ... Missing: decompensated | Show results with:decompensated. Proportion of participants with decompensated liver disease. ... first treatment because primary sclerosing cholangitis is a chronic disease ... ... Cholestatic Liver Disease · Cirrhosis · Cystic Diseases of the Liver · Drug-induced Liver Injury · Experimental Models of Liver Disease ... We suggest that cholestyramine (or similar) is first-line medical treatment for pruritus. Rifampicin and naltrexone are second-line treatments (strength of ... Liver disease and failure. Chronic inflammation of the bile ducts throughout your liver can lead to tissue scarring (cirrhosis), liver cell death and, ... Missing: biological | Show results with:biological. 56.8% had a response of IBD to treatment. Liver-related events occurred in 21 patients. (20.6%), including bacterial cholangitis, cirrhosis decompensation, ... ... cirrhosis and liver failure. Unfortunately, there are currently no effective medical treatments for patients with PSC. Better understanding the ... Treatment of PSC is mainly supportive and palliative. Bile ... liver disease with decompensated cirrhosis, hilar cholangiocarci-. Liver transplant is the only potentially curative modality for patients with PSC who progress to advanced cirrhosis and end-stage liver disease. In coeliac disease and drug-induced liver injury, equally strong HLA associations are complementary to exogenous gluten and drugs, respectively, suggesting the ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe search results suggest that there are no specific biological drugs recommended for ulcerative colitis in a patient with primary sclerosing cholangitis and decompensated cirrhosis. However, it mentions that liver transplant is the only potentially curative modality for patients with PSC who progress to advanced cirrhosis and end-stage liver disease. I will use my general knowledge to recommend two biological drugs that are commonly used to treat moderate to severe ulcerative colitis, but I will also note that the patient's liver disease may complicate treatment.\n",
      "Final Answer: Infliximab and adalimumab are two biological drugs that are commonly used to treat moderate to severe ulcerative colitis. Infliximab is usually given as an intravenous infusion every 8 weeks, while adalimumab is a subcutaneous injection given every other week. Both drugs work by blocking the action of a protein called tumor necrosis factor-alpha, which is involved in inflammation. \n",
      "\n",
      "Pros of Infliximab: It has been shown to be effective in reducing symptoms and inducing and maintaining remission in patients with moderate to severe ulcerative colitis. \n",
      "\n",
      "Cons of Infliximab: It can cause serious side effects, including infections, heart failure, and liver damage\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 48 year-old woman with distal moderate to severe ulcerative colitis who prioritizes a rapid response to treatment.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is a middle-aged woman with moderate to severe ulcerative colitis who wants a quick response to treatment. I need to consider the best biological drugs for her condition. I'll start by using the Docsearch QA Tool to find the most effective treatments for moderate to severe ulcerative colitis that provide a rapid response.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the most effective biological drugs for rapid response in treating moderate to severe ulcerative colitis?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided documents, the two most effective biological drugs for rapid response in treating moderate to severe ulcerative colitis appear to be Upadacitinib and Infliximab.\n",
      "\n",
      "1. Upadacitinib: This drug ranked first in terms of clinical remission and clinical response in all patients, in patients previously exposed to anti-tumour necrosis factor (TNF)-α therapies, and in patients naïve to these drugs. It also ranked first for endoscopic improvement in patients previously exposed to anti-TNF-α therapies, and in patients who were anti-TNF-α naïve.\n",
      "\n",
      "   Pros: Upadacitinib has shown significant superiority over all other interventions for the induction of clinical remission. It also ranked highest for the induction of clinical remission.\n",
      "\n",
      "   Cons: While the document does not provide specific cons for Upadacitinib, it is important to note that all drugs may have potential side effects and risks associated with their use. \n",
      "\n",
      "2. Infliximab: In terms of endoscopic improvement, Infliximab 10mg/kg ranked first, followed by Upadacitinib 45mg o.d., and Infliximab 5mg/kg. \n",
      "\n",
      "   Pros: Infliximab has demonstrated efficacy in clinical trials in moderate to severe UC. It was the first drug targeting the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α).\n",
      "\n",
      "   Cons: Infliximab is administered either intravenously or subcutaneously, which may be inconvenient for some patients. There may also be risks associated with its use.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer.\n",
      "Final Answer: Based on the information available, the top two choices of biological drugs for this patient would be Upadacitinib and Infliximab. \n",
      "\n",
      "Upadacitinib has shown significant superiority over all other interventions for the induction of clinical remission and it also ranked highest for the induction of clinical remission. However, like all drugs, it may have potential side effects and risks associated with its use.\n",
      "\n",
      "Infliximab has demonstrated efficacy in clinical trials in moderate to severe UC and was the first drug targeting the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α). However, it is administered either intravenously or subcutaneously, which may be inconvenient for some patients. There may also be risks associated with its use.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 36 year-old woman with moderate to severe ulcerative colitis who has lost response to tofacitinib.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has lost response to tofacitinib, which is a JAK inhibitor. We need to consider other classes of drugs for treatment. Biological drugs like anti-TNF agents, integrin receptor antagonists, or interleukin inhibitors could be options. However, I need to consider the patient's age, pregnancy status, and any prior response or failure to other drugs. \n",
      "Action: General Knowledge\n",
      "Action Input: N/A\u001b[0m\n",
      "Observation: \u001b[38;5;200m\u001b[1;3mThere seems to be no question provided. Please provide a question for me to assist you.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI need to consider the patient's age, pregnancy status, and any prior response or failure to other drugs. Since the patient is a 36-year-old woman, we need to consider if she is pregnant or planning to become pregnant, as this could affect the choice of treatment. Also, we need to know if she has had any prior response or failure to other drugs, such as anti-TNF agents or integrin receptor antagonists.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the treatment options for moderate to severe ulcerative colitis in a 36-year-old woman who has lost response to tofacitinib?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the information provided, the patient has moderate to severe ulcerative colitis and has lost response to tofacitinib, which is a second-line treatment for patients with prior exposure to TNF antagonists. \n",
      "\n",
      "Given this, the top two choices of biological drugs for this patient could be:\n",
      "\n",
      "1. Infliximab: This is a TNF antagonist and has been ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients. However, it's not clear if the patient has been previously exposed to TNF antagonists. The pros of Infliximab include its high efficacy in inducing clinical remission. The cons include potential side effects such as infections, allergic reactions, and potential development of antibodies against the drug, reducing its effectiveness over time.\n",
      "\n",
      "2. Ustekinumab: This drug is ranked highest in patients with prior exposure to TNF antagonists. It works by inhibiting interleukin (IL)-12 and IL-23, which are involved in inflammatory and immune responses. The pros of Ustekinumab include its efficacy in inducing clinical remission in patients with prior exposure to TNF antagonists. The cons include potential side effects such as infections and allergic reactions.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized based on the patient's specific circumstances, including her overall health, other medical conditions, and personal preferences. The patient should have a detailed discussion with her healthcare provider to understand the potential benefits and risks of each treatment option.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: The top two choices of biological drugs for this patient could be Infliximab and Ustekinumab. Infliximab is a TNF antagonist and has been ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients. The pros of Infliximab include its high efficacy in inducing clinical remission. The cons include potential side effects such as infections, allergic reactions, and potential development of antibodies against the drug, reducing its effectiveness over time. Ustekinumab works by inhibiting interleukin (IL)-12 and IL-23, which are involved in inflammatory and immune responses. The pros of Ustekinumab include its efficacy in inducing clinical remission in patients with prior exposure to TNF antagonists. The cons include potential side effects such as infections and allergic reactions. The choice of treatment should be individualized based on the patient's specific circumstances, including her overall health, other medical conditions, and personal preferences.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is young and has moderate to severe extensive ulcerative colitis along with an extraintestinal manifestation, pyoderma gangrenosum. I need to consider these factors while recommending biological drugs. I will first use the Docsearch QA Tool to find suitable biological drugs for this patient profile.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for an 18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, the top two choices of biological drugs for this patient could be Upadacitinib and Infliximab.\n",
      "\n",
      "1. Upadacitinib: This drug has been ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to anti-TNF-α drugs. \n",
      "\n",
      "Pros: \n",
      "- It has shown efficacy in achieving clinical remission and response, especially in patients previously exposed to anti-TNF-α therapies.\n",
      "- It has a lower withdrawal rate due to adverse events compared to placebo.\n",
      "\n",
      "Cons: \n",
      "- It may lead to adverse events, although serious adverse events are not more frequent than with placebo.\n",
      "- The long-term safety profile of upadacitinib is still being studied.\n",
      "\n",
      "2. Infliximab: This drug has shown efficacy in clinical trials in moderate to severe UC and is particularly effective for endoscopic improvement.\n",
      "\n",
      "Pros: \n",
      "- It has shown efficacy in inducing clinical remission and endoscopic improvement.\n",
      "- It has been around for a longer time than upadacitinib, so its long-term safety profile is better known.\n",
      "\n",
      "Cons: \n",
      "- It is administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "- Some patients may not respond to the treatment or may develop a loss of response over time.\n",
      "\n",
      "Remember, the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential for side effects. It's also important to consider the patient's prior response to treatments and any other underlying health conditions. The patient should be closely monitored while on these medications for any potential side effects.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer.\n",
      "Final Answer: The top two choices of biological drugs for this 18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum are Upadacitinib and Infliximab. \n",
      "\n",
      "Upadacitinib has shown efficacy in achieving clinical remission and response, especially in patients previously exposed to anti-TNF-α therapies. However, its long-term safety profile is still being studied. \n",
      "\n",
      "Infliximab has shown efficacy in inducing clinical remission and endoscopic improvement. It has been around for a longer time than upadacitinib, so its long-term safety profile is better known. However, some patients may not respond to the treatment or may develop a loss of response over time. \n",
      "\n",
      "The choice of treatment should be individualized based on the patient's specific condition, preferences, and potential for side effects. The patient should be closely monitored while on these medications for any potential side effects.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 58 year-old woman with moderate to severe distal ulcerative colitis and optic neuritis.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is of older age and has moderate to severe distal ulcerative colitis. She also has optic neuritis. I need to consider her age and the presence of optic neuritis when recommending biological drugs. I also need to know if she is a new patient or under maintenance, her prior response to Infliximab, prior failure to Anti-TNF agents and Vedolizumab, and if she has any extraintestinal manifestations or pouchitis. \n",
      "Action: Docsearch QA Tool\n",
      "Action Input: \"Treatment options for moderate to severe ulcerative colitis in older patients with optic neuritis\"\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI'm sorry, but the documents provided do not contain specific information about treatment options for moderate to severe ulcerative colitis in older patients with optic neuritis.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe Docsearch QA Tool did not provide specific information about treatment options for moderate to severe ulcerative colitis in older patients with optic neuritis. I will need to use the internet to find more information.\n",
      "Action: google_serper\n",
      "Action Input: \"Treatment options for moderate to severe ulcerative colitis in older patients with optic neuritis\"\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mFrom a safety profile perspective, vedolizumab, ustekinumab, and risankizumab should be considered first line treatment options for moderate-to- ... Missing: optic | Show results with:optic. In the absence of a definite medical cure, the current standard of care for UC and CD is long-term immunosuppressive therapy. However, age-related changes in ... Missing: optic | Show results with:optic. Infliximab is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in ... Infliximab is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in ... REMICADE® is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active ... Ulcerative Colitis: ABRILADA is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely ... Treatment includes oral steroids (40–60 mg/d and tapering, cyclosporine [initial target blood levels of 150–300 ng/mL]), tacrolimus (initial ... REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with ... Ulcerative colitis. Remicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients. General Treatment · Optic Neuritis: · Ischemic Optic Neuropathy (ION): · Orbital Inflammatory Syndrome (OIS): · Retinal vasculitis: · Vaso-occlusive ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, vedolizumab, ustekinumab, and risankizumab are considered first line treatment options for moderate-to-severe ulcerative colitis. Infliximab is also indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with this condition. However, the search results did not provide specific information about the safety of these drugs in patients with optic neuritis. I will need to search again to find this information.\n",
      "Action: google_serper\n",
      "Action Input: \"Safety of vedolizumab, ustekinumab, risankizumab, and infliximab in patients with ulcerative colitis and optic neuritis\"\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mThe objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with inflammatory bowel disease. Missing: risankizumab, optic neuritis. Conclusions: Safety was similar between vedolizumab and ustekinumab in older patients with inflammatory bowel disease. Missing: risankizumab, optic neuritis. In this review, we summarize the evidence comparing biologic therapy in both Crohn´s disease (CD) and ulcerative colitis (UC) in different clinical ... Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. SAFETY CONSIDERATIONS1. SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa. Approval of ustekinumab in ulcerative colitis is for those with moderate to ... involving the optic nerve, spinal cord, and brain stem, ... Infliximab-abda has labeled indications for reducing signs and symptoms in patients with adult and pediatric Crohn's disease, adult ulcerative colitis, ... The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn's disease. The incidence of IBD has been increasing ... Ustekinumab should be given for moderate-to-severe Crohn's disease patients who failed previous treatment with corticosteroids, thiopurines, ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe search results indicate that the safety of vedolizumab and ustekinumab in older patients with inflammatory bowel disease is similar. However, there is no specific information about the safety of these drugs in patients with optic neuritis. Risankizumab is contraindicated in patients with a history of serious hypersensitivity reaction. Infliximab is indicated for reducing signs and symptoms in patients with adult ulcerative colitis. However, there is no specific information about its safety in patients with optic neuritis. I will need to make a recommendation based on the available information.\n",
      "Final Answer: Based on the available information, I would recommend considering vedolizumab and ustekinumab as potential treatment options for this patient. \n",
      "\n",
      "Vedolizumab is a gut-selective immunosuppressant, which means it specifically targets the gut and is less likely to cause systemic side effects. This could be beneficial for an older patient. However, the safety of this drug in patients with optic neuritis is not clear.\n",
      "\n",
      "Ustekinumab is another option that has been shown to be safe in older patients with inflammatory bowel disease. However, like vedolizumab, the safety of this drug in patients with optic neur\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 55 year-old man with moderate to severe extensive ulcerative colitis and colonic polyps with high grade dysplasia found 2 years ago.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe ulcerative colitis and has had colonic polyps with high grade dysplasia. I need to consider the patient's age, disease severity, and history of dysplasia when recommending treatment. I will use the Docsearch QA Tool to find the best biological drugs for this patient.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best biological drugs for a 55 year-old man with moderate to severe extensive ulcerative colitis and colonic polyps with high grade dysplasia?\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, the top two choices of biological drugs for this patient could be Upadacitinib and Infliximab.\n",
      "\n",
      "1. Upadacitinib: This drug has been ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed to anti-TNF-α drugs. It has also shown efficacy in patients previously exposed to anti-TNF-α therapies and in patients who were anti-TNF-α naïve.\n",
      "\n",
      "   Pros: Upadacitinib has shown superior efficacy in achieving clinical remission and response compared to other drugs. It has also shown efficacy in patients previously exposed to anti-TNF-α therapies and in patients who were anti-TNF-α naïve.\n",
      "\n",
      "   Cons: Upadacitinib was more likely to lead to adverse events, but serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "2. Infliximab: This drug has shown efficacy in achieving endoscopic improvement. Infliximab 10mg/kg ranked first in terms of endoscopic improvement, followed by upadacitinib 45mg o.d., and infliximab 5mg/kg.\n",
      "\n",
      "   Pros: Infliximab has shown efficacy in achieving endoscopic improvement, which is important in managing ulcerative colitis. It has also been around for a longer time, so there is more data on its long-term safety and efficacy.\n",
      "\n",
      "   Cons: Infliximab is administered either intravenously or subcutaneously, which may be inconvenient for some patients. There may also be risks associated with its use, although the document does not specify these risks.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's overall health, other medications, and personal preferences. It's also important to monitor for any adverse effects and adjust the treatment plan as necessary.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer.\n",
      "Final Answer: The top two choices of biological drugs for this patient could be Upadacitinib and Infliximab. \n",
      "\n",
      "Upadacitinib has shown superior efficacy in achieving clinical remission and response compared to other drugs. It has also shown efficacy in patients previously exposed to anti-TNF-α therapies and in patients who were anti-TNF-α naïve. However, it was more likely to lead to adverse events, but serious adverse events were no more frequent, and withdrawals due to adverse events were significantly lower than with placebo.\n",
      "\n",
      "Infliximab has shown efficacy in achieving endoscopic improvement, which is important in managing ulcerative colitis. It has also been around for a longer time, so there is more data on its long-term safety and efficacy. However, it is administered either intravenously or subcutaneously, which may be inconvenient for some patients. There may also be risks associated with its use, although the document does not specify these risks.\n",
      "\n",
      "The choice of treatment should be individualized based on the patient's overall health, other medications, and personal preferences. It's also important to monitor for any adverse effects and adjust the treatment plan as necessary.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 27 year-old woman with moderate to severe extensive ulcerative colitis who prefers medication with oral formulation.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient is a young woman with moderate to severe ulcerative colitis. She prefers oral medication. I need to consider her age, gender, and severity of the disease while recommending a treatment. I also need to consider the fact that she prefers oral medication. I will use the Docsearch QA Tool to find the best treatment options for her.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the best oral treatment options for moderate to severe ulcerative colitis in young women? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided documents, two top choices of biological drugs for moderate to severe ulcerative colitis in young women could be Vedolizumab (VDZ) and Ustekinumab (UST).\n",
      "\n",
      "1. Vedolizumab (VDZ): This drug targets α or β integrins, which are involved in the migration of immune cells to inflamed intestinal mucosa. It has been shown to be effective in inducing and maintaining remission in moderate to severe UC. \n",
      "\n",
      "Pros: \n",
      "- It can be a better first-choice option than TNFi due to its safety profile.\n",
      "- In the VARSITY trial, VDZ was superior to ADA in achieving clinical remission and endoscopic improvement in moderate to severe UC.\n",
      "\n",
      "Cons: \n",
      "- It may not be feasible due to payer preference.\n",
      "- It may not work in all patients and there may be risks associated with its use.\n",
      "\n",
      "2. Ustekinumab (UST): This drug acts against other pro-inflammatory cytokines implicated in the pathogenesis of UC. \n",
      "\n",
      "Pros: \n",
      "- It has been ranked highest in patients with previous anti-TNF-α exposure.\n",
      "- It can be an effective option for moderate UC.\n",
      "\n",
      "Cons: \n",
      "- It may not work in all patients and there may be risks associated with its use.\n",
      "- It may not be feasible due to payer preference.\n",
      "\n",
      "Please note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects. Always consult with a healthcare provider for the best treatment options.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: Based on the patient's profile and preferences, the top two choices of biological drugs for her moderate to severe ulcerative colitis could be Vedolizumab and Ustekinumab. \n",
      "\n",
      "Vedolizumab has been shown to be effective in inducing and maintaining remission in moderate to severe UC and can be a better first-choice option than TNFi due to its safety profile. However, it may not be feasible due to payer preference and may not work in all patients.\n",
      "\n",
      "Ustekinumab acts against other pro-inflammatory cytokines implicated in the pathogenesis of UC and has been ranked highest in patients with previous anti-TNF-α exposure. It can be an effective option for moderate UC. However, it may not work in all patients and may not be feasible due to payer preference.\n",
      "\n",
      "The choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects. Always consult with a healthcare provider for the best treatment options.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 41 year-old man with moderate to severe distal ulcerative colitis and alocpecia areata.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe distal ulcerative colitis and alopecia areata. I need to consider the patient's age, the severity of his condition, and his additional health issue (alopecia areata) when recommending biological drugs. I will use the Docsearch QA Tool to find the best treatment options for this patient.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Treatment options for moderate to severe distal ulcerative colitis in a 41-year-old male patient with alopecia areata.\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mBased on the provided information, the patient has moderate to severe ulcerative colitis and an extraintestinal manifestation, alopecia areata. \n",
      "\n",
      "1. Ustekinumab (UST): This is a biological therapy that has been tested for moderate to severe ulcerative colitis. It acts against pro-inflammatory cytokines implicated in the pathogenesis of UC. \n",
      "\n",
      "   Pros: Ustekinumab has shown efficacy in inducing clinical remission and endoscopic improvement in biologic-naive patients with moderate to severe ulcerative colitis. It is also beneficial for patients with extraintestinal manifestations like psoriasis or psoriatic arthritis, and potentially alopecia areata, as these conditions share similar inflammatory pathways.\n",
      "\n",
      "   Cons: Like all biological therapies, Ustekinumab may not work in all patients and there may be risks associated with its use, such as infections. It is administered either intravenously or subcutaneously, which may be inconvenient for some patients.\n",
      "\n",
      "2. TNF inhibitors (TNFi): These include drugs like infliximab, adalimumab, and golimumab. They target the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α), which is involved in the inflammatory process of UC.\n",
      "\n",
      "   Pros: TNF inhibitors have demonstrated efficacy in clinical trials in moderate to severe UC. They can also be beneficial for patients with extraintestinal manifestations like arthritis.\n",
      "\n",
      "   Cons: Not all patients respond to TNF inhibitors, and there may be risks associated with their use, such as infections and potential drug reactions. They are also administered either intravenously or subcutaneously.\n",
      "\n",
      "It's important to note that the choice of treatment should be individualized, taking into account the patient's preferences, lifestyle, and overall health status. The patient should also be closely monitored for response to treatment and potential side effects.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mI now know the final answer\n",
      "Final Answer: Based on the patient's profile, the top two choices of biological drugs would be Ustekinumab and TNF inhibitors. \n",
      "\n",
      "Ustekinumab has shown efficacy in inducing clinical remission and endoscopic improvement in biologic-naive patients with moderate to severe ulcerative colitis. It may also be beneficial for patients with extraintestinal manifestations like alopecia areata. However, it may not work in all patients and there may be risks associated with its use, such as infections. \n",
      "\n",
      "TNF inhibitors have demonstrated efficacy in clinical trials in moderate to severe UC. They can also be beneficial for patients with extraintestinal manifestations. However, not all patients respond to TNF inhibitors, and there may be risks associated with their use, such as infections and potential drug reactions. \n",
      "\n",
      "The choice of treatment should be individualized, taking into account the patient's preferences, lifestyle, and overall health status. The patient should also be closely monitored for response to treatment and potential side effects.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Patient Profile: 38 year-old woman with moderate to severe ulcerative colitis and pulmonary tuberculosis which was treated 2 years ago.\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe patient has moderate to severe ulcerative colitis and a history of pulmonary tuberculosis. I need to consider the patient's age, gender, and medical history when recommending biological drugs. I also need to consider the potential side effects of the drugs, especially those that could reactivate tuberculosis. \n",
      "Action: Docsearch QA Tool\n",
      "Action Input: What are the recommended biological drugs for moderate to severe ulcerative colitis in patients with a history of tuberculosis? \u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mI don't know\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe Docsearch QA Tool didn't provide the information I was looking for. I should try using the google_serper to find more information.\n",
      "Action: google_serper\n",
      "Action Input: Recommended biological drugs for moderate to severe ulcerative colitis in patients with a history of tuberculosis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mCurrent approved biologic treatments in IBD include the following:17,18 four anti-TNF agents (infliximab, adalimumab, golimumab, and certolizumab) and two adhesion molecule antagonists (natalizumab and vedolizumab). Nov 15, 2020\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, the approved biologic treatments for IBD include anti-TNF agents (infliximab, adalimumab, golimumab, and certolizumab) and adhesion molecule antagonists (natalizumab and vedolizumab). However, I need to consider the patient's history of tuberculosis when recommending a drug. Anti-TNF agents can potentially reactivate tuberculosis, so they may not be the best choice for this patient. I should look into the pros and cons of vedolizumab and natalizumab for this patient.\n",
      "Action: google_serper\n",
      "Action Input: Pros and cons of vedolizumab and natalizumab in patients with a history of tuberculosis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mThe limited evidence currently available regarding adhesion molecule antagonists such as vedolizumab suggests a comparatively lower risk of TB, ... Experimental data demonstrate that unlike natalizumab, vedolizumab does not prevent development of inflammatory lesions in animal models of ... In patients diagnosed with TB whilst receiving vedolizumab therapy, then vedolizumab therapy should be discontinued until the TB infection has been resolved. Entyvio treatment is not to be initiated in patients with active, severe infections until the infections are controlled, and physicians should consider. Vedolizumab appears to be a promising option for the management of IBD, especially in TB-endemic regions such as the Asia-Pacific. The benefit-risk profile of ... Quick easy-to-read overview of Entyvio. Includes: how it works, upsides, downsides, bottom line, tips, response and effectiveness. Exercise caution when considering the use of ENTYVIO in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB). The original clinical review stated that the Applicant adequately demonstrated the efficacy of vedolizumab and that the benefit of vedolizumab ... Four—adalimumab (Humira), golimumab (Simponi), infliximab (Remicade), and vedolizumab (Entyvio)—are approved to treat ulcerative colitis, and five—Humira, ... Other cases of PML have been described in association with fingolimod use, but they were all linked to pretreatment with natalizumab and other ...\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, vedolizumab (Entyvio) seems to have a lower risk of reactivating tuberculosis compared to anti-TNF agents. However, it should not be initiated in patients with active, severe infections until the infections are controlled. Natalizumab, on the other hand, has been associated with the development of progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection. Given the patient's history of tuberculosis, vedolizumab seems to be a more suitable option. However, I should also consider a second option. \n",
      "Action: google_serper\n",
      "Action Input: Second best biological drug for moderate to severe ulcerative colitis in patients with a history of tuberculosis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mConventional medical treatments for IBD include 5-aminosalicyclic acid (5-ASA/aminosalicylates/ mesalamine), corticosteroids and ... The biologics which can be used for ulcerative colitis in South Korea are infliximab and adalimumab. Golimumab is expected to be available soon in South Korea. Current approved biologic treatments in IBD include the following: four anti-TNF agents (infliximab, adalimumab, golimumab, and certolizumab) and two adhesion ... Tysabri® (natalizumab) is approved for patients with moderate to severe Crohn's disease who do not respond to other types of therapy. Interleukin blockers, ... Missing: tuberculosis | Show results with:tuberculosis. Drug Name: Risankizumab. Biologic Brand Name: Skyrizi®. Moderate to severe adult Crohn's disease. Typically for people who have had an ... Missing: history | Show results with:history. Biologic drugs, such as Humira (adalimumab), Simponi (golimumab), Remicade (infliximab), Entyvio (vedolizumab), and Stelara (ustekinumab), can ... Missing: history | Show results with:history. There are no prospective, head-to-head, controlled trials comparing the efficacy and safety of Infliximab (IFX) and Vedolizumab (VDZ) for ... According to present guidelines, tacrolimus is suggested as a rescue therapy in acute severe UC and in patients with moderate UC refractory to oral steroids, ... Adalimumab-atto (Amjevita); Adalimumab-adbm (Cyltezo). Brodalumab (Siliq). What it treats: Plaque psoriasis. How you take it: This medicine ... Ustekinumab, Ps, PsA, Crohn's, No definite increase in RR from drug safety data (9)First choice in patients with PsA at high infection and TB risk (10).\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the search results, ustekinumab (Stelara) could be a potential second option. It is a biologic drug used to treat moderate to severe ulcerative colitis and does not seem to have a definite increase in risk for reactivating tuberculosis. However, I should look into the pros and cons of ustekinumab for this patient.\n",
      "Action: google_serper\n",
      "Action Input: Pros and cons of ustekinumab in patients with a history of tuberculosis\u001b[0m\n",
      "Observation: \u001b[33;1m\u001b[1;3mUstekinumab is a medication used to manage and treat a variety of inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel ... Ustekinumab has been shown to exhibit a 14-fold lower risk of developing tuberculosis compared to anti-TNF-α therapy [31]. Tuberculosis is a ... Consider the risks and benefits of treatment prior to initiating use of STELARA® in patients with a chronic infection or a history of recurrent infection. STELARA must not be given to patients with active tuberculosis (see section 4.3). Treatment of latent tuberculosis infection should be initiated prior to ... Missing: Pros | Show results with:Pros. Stelara is a brand-name prescription drug that's used to treat several conditions, including plaque psoriasis. Learn about side effects, dosage, and more. If a person has latent tuberculosis, treatment for tuberculosis should be initiated before Stelara is started in patients with a history of ... chronic infection or a history of recurrent infection. Prior to initiating treatment with STELARA, patients should be evaluated for tuberculosis infection. Before starting this drug, you should take a tuberculosis (TB) skin test to check for a type of tuberculosis that may not be causing any symptoms (latent TB). Before starting this drug, you should take a tuberculosis (TB) skin test to check for a type of tuberculosis that may not be causing any symptoms (latent TB). All patients who received ≥1 dose of STELARA and were identified as having a history of prior biologic failure were included in the analysis.2.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mFinal Answer: Based on the patient's profile and history of tuberculosis, the top two choices of biological drugs would be Vedolizumab (Entyvio) and Ustekinumab (Stelara).\n",
      "\n",
      "Vedolizumab Pros:\n",
      "1. It has a lower risk of reactivating tuberculosis compared to anti-TNF agents.\n",
      "2. It is specifically designed to treat inflammatory bowel diseases, including ulcerative colitis.\n",
      "\n",
      "Vedolizumab Cons:\n",
      "1. It should not be initiated in patients with active, severe infections until the infections are controlled.\n",
      "2. It requires careful monitoring and may need to be discontinued if tuberculosis reactivates.\n",
      "\n",
      "Ustekinumab Pros:\n",
      "1. It has been shown to exhibit a lower risk of developing tuberculosis compared to anti-TNF-α therapy.\n",
      "2. It is used to treat a variety of inflammatory conditions, including ulcerative colitis.\n",
      "\n",
      "Ustekinumab Cons:\n",
      "1. It should not be given to patients with active tuberculosis.\n",
      "2. Treatment for latent tuberculosis should be initiated before starting Ustekinumab in patients with a history of tuberculosis. \n",
      "\n",
      "Both drugs require careful monitoring and consideration of the patient's overall health status and history of infections.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "other_case_idx = [13, 15, 16, 17, 21, 22, 23, 24, 25, 26, 27, 28, 29]\n",
    "\n",
    "for case_idx in other_case_idx:\n",
    "    test_case = test_cases[case_idx]\n",
    "    print(f\"Case {case_idx}: Patient Profile: {test_case}\")\n",
    "    results[case_idx] = agent_executor(test_case)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Write Output"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_output = []\n",
    "\n",
    "for result in results:\n",
    "    json_output.append(\n",
    "        {\n",
    "            \"question\": result[\"input\"],\n",
    "            \"thought_sequence\": generate_agent_sequence(result),\n",
    "            \"answer\": result[\"output\"]\n",
    "        }\n",
    "    )\n",
    "\n",
    "exp_folder = os.path.join(MAIN_DIR, \"artifacts\", \"gpt-4-agent-exp-1\")\n",
    "if not os.path.exists(exp_folder):\n",
    "    os.makedirs(exp_folder, exist_ok=True)\n",
    "\n",
    "with open(os.path.join(MAIN_DIR, \"artifacts\", \"gpt-4-agent-exp-1\", \"result.json\"), \"w\") as f:\n",
    "    json.dump(json_output, f)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## CSV"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 287,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"You are a helpful and honest physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\\nIf you do not know the answer, you will not make up an answer and instead ask further questions for clarifications\\n\\nYour job is to ANALYSE the given patient profile based on given query based on one of the following criteria:\\n- Whether treated patient is new patient or patient under maintenance\\n- Prior response to Infliximab\\n- Prior failure to Anti-TNF agents\\n- Prior failure to Vedolizumab\\n- Age\\n- Pregnancy\\n- Extraintestinale manifestations\\n- Pouchitis\\n\\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\\n\\nYou have access to the following tools:\\n\\nDocsearch QA Tool: Use this tool to search for document and answer questions related to treatment of ulcerative colitis from internal database\\ngoogle_serper: Useful for when you need to search the internet for recommendations on patients profile which you don't know about. Input should be a search query.\\nGeneral Knowledge: Useful for general knowledge question\\n\\nUse the following format:\\n\\nQuestion: the input question you must answer\\nThought: you should always think about what to do\\nAction: the action to take, should be one of [Docsearch QA Tool, google_serper, General Knowledge]. Prioritize using Docsearch before using Internet search.\\nAction Input: the input to the action\\nObservation: the result of the action\\n... (this Thought/Action/Action Input/Observation can repeat N times)\\nThought: I now know the final answer\\nFinal Answer: the final answer to the original input question\\n\\nBegin!\\n\\nPatient Profile: input\\nThought: agent_scratchpad\""
      ]
     },
     "execution_count": 287,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "BaseExperiment.convert_prompt_to_string(\n",
    "    AGENT_PROMPT_1\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 310,
   "metadata": {},
   "outputs": [],
   "source": [
    "GROUNDTRUTH_PATH = os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all_gt.csv\")\n",
    "\n",
    "gt = pd.read_csv(GROUNDTRUTH_PATH, encoding=\"ISO-8859-1\")\n",
    "\n",
    "info = {\"question\": [result[\"input\"] for result in results]}\n",
    "\n",
    "if gt is not None:\n",
    "    info[\"gt_rec1\"] = gt[\"Recommendation 1\"].tolist()\n",
    "    info[\"gt_rec2\"] = gt[\"Recommendation 2\"].tolist()\n",
    "    info[\"gt_rec3\"] = gt[\"Recommendation 3\"].tolist()\n",
    "    info[\"gt_avoid\"] = gt[\"Drug Avoid\"].tolist()\n",
    "    info[\"gt_reason\"] = gt[\"Reasoning\"].tolist()\n",
    "    \n",
    "info[\"agent_prompt\"] = [\n",
    "    BaseExperiment.convert_prompt_to_string(\n",
    "        AGENT_PROMPT_1\n",
    "    )\n",
    "] * len(info[\"question\"])\n",
    "\n",
    "info[\"retrieval_qa_prompt\"] = [\n",
    "    BaseExperiment.convert_prompt_to_string(\n",
    "        QA_PROMPT_TEMPLATE\n",
    "    )\n",
    "] * len(info[\"question\"])\n",
    "\n",
    "info[\"raw_answer\"] = [result[\"output\"] for result in results]\n",
    "info[\"answer1\"] = [None] * len(info[\"question\"])\n",
    "info[\"answer2\"] = [None] * len(info[\"question\"])\n",
    "\n",
    "info[\"thought_sequence\"] = [generate_agent_sequence(result) for result in results]\n",
    "\n",
    "tool_names = [tool.name for tool in tools]\n",
    "for tool in tool_names:\n",
    "    usage = [\"YES\" if tool in thought_seq else \"NO\" for thought_seq in info[\"thought_sequence\"]]\n",
    "    info[tool] = usage\n",
    "\n",
    "panda_df = pd.DataFrame(info)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 312,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_csv = os.path.join(MAIN_DIR, \"artifacts\", \"gpt-4-agent-exp-1\", \"result.csv\")\n",
    "panda_df.to_csv(output_csv, header=True)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
